BACKGROUND: The present study reviews our 12-year results with cytoreductive 
surgery and HIPEC in patients with advanced primary and recurrent ovarian 
cancer.
METHODS: During the period from January 1995 to December 2007, 56 patients (31 
with primary and 25 with recurrent epithelial ovarian cancer) underwent 
cytoreductive surgery and HIPEC (Doxorubicin intra-operatively, and cisplatin 
next 1-5 postoperative days) at our department.
RESULTS: 52 (92.8%) patients had no gross residual disease after the complete 
surgical procedure (Sugarbaker completeness of cytoreduction CC, score 0-1), and 
4 patients had macroscopic residual disease (CC-2 or CC-3) Average PCI 
(peritoneal cancer index) was 13.4 (4-28). Mean follow-up was 56 months (range, 
1-135). The median operation time was 279min (range 190 + or - 500min). Median 
total blood loss was 850mL (range 250 + or - 1550mL). The median survival time 
was 34.1 months for primary, 40.1 for recurrent ovarian cancer without 
statistically significance difference (p>0.05) and median disease-free survival 
was 26.2 months. The PCI was equal or less than 12 in 31 patients and their 
median survival time was statistically significant longer than median survival 
time of months for the 25 patients with PCI greater then 12 (p<0.01). Morbidity 
and mortality rate were 17.8% (10/56) and 1.8% (1/56).
CONCLUSION: This series indicates that in the majority of patients with primary 
and recurrent advanced ovarian cancer, cytoreductive surgery combined with HIPEC 
can lead to a substantial increase in subsequent rates of disease-free and 
overall survival.